Atossa Genetics - Seeking to prevent or treat breast cancer
Atossa Genetics reported Phase I data on its topical endoxifen formulation and it is now developing this as a potential treatment for high...
213 Views
Funded into Q417, endoxifen now in Phase I
Atossa raised $4.4m in April 2017 in an equity raise consisting of common shares, Series A convertible preferred shares (SACPS), and warrants. We...
279 Views
Atossa to raise $4.0m in combined class offering
Atossa intends to raise $4.0m (gross proceeds), excluding over-allotments, in an equity offering of Class A and Class B units, consisting of 0.664m...
179 Views